ArticleCurrent opinion in investigational drugs (London, England : 2000)2010
Targeting the IL-1 family members in skin inflammation.
Article in Current opinion in investigational drugs (London, England : 2000), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 66 citations in OpenAlex.
- Interleukin-1α inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studies.Archives of dermatological research · 2024Trial
- Trial
- Exploring novel skin biomarkers related to pruritus in dialysis patients.International urology and nephrology · 2026Article
- Development of a controlled ex vivo human skin platform for quantitative evaluation of age-related functional biomarkers following application of topical treatments.Scientific reports · 2026Article
- IL-1 signaling enrichment in inflammatory skin disease loci with higher-risk allele frequencies in African ancestry.Research square · 2025Article
- Exploring the effect of hsa-miR-19b-3p on IL-1R1 expression and serum levels in alopecia areata.Archives of dermatological research · 2025Article
- Evaluation test and analysis of a microneedle and iontophoresis based medical device "CELLADEEP Patch" in skin improvement on ex vivo human-derived skin tissue models.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- A Polygenic Risk Score for Predicting Racial and Genetic Susceptibility to Prurigo Nodularis.The Journal of investigative dermatology · 2023Article
- Inflammatory biomarkers in sebum for identifying skin damage in patients with a Stage I pressure ulcer in the pelvic region: A single centre observational, longitudinal cohort study with elderly patients.International wound journal · 2023Observational
- Review
- The Endogenous Dual Retinoid Receptor Agonist Alitretinoin Exhibits Immunoregulatory Functions on Antigen-Presenting Cells.International journal of molecular sciences · 2023Article
- Evaluation of interleukin-33 & sST2 levels in type-2 diabetic mellitus patients with or without metabolic syndrome.The Indian journal of medical research · 2023Article
- Probiotics for the Management of Oral Mucositis: An Interpretive Review of Current Evidence.Advanced pharmaceutical bulletin · 2023Review
- Biophysical and biochemical changes in skin health of healthcare professionals using respirators during COVID-19 pandemic.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2023Article
- Article
- Cluster Analysis of Circulating Plasma Biomarkers in Prurigo Nodularis Reveals a Distinct Systemic Inflammatory Signature in African Americans.The Journal of investigative dermatology · 2022Article
- Paclitaxel-Induced Epidermal Alterations: An In Vitro Preclinical Assessment in Primary Keratinocytes and in a 3D Epidermis Model.International journal of molecular sciences · 2022Article
- Advances in pathogenesis and nanoparticles (NPs)-mediated treatment of psoriasis.Frontiers in immunology · 2022Review
- Synthesis of Retinol-Loaded Lipid Nanocarrier via Vacuum Emulsification to Improve Topical Skin Delivery.Polymers · 2021Article
- Hippophae rhamnoides mediate gene expression profiles against keratinocytes infection of Staphylococcus aureus.Molecular biology reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The IL-1 family of cytokines comprises 11 proteins with pro- and anti-inflammatory functions that are mediated through an equally large group of receptors and coreceptors. Dysregulation of the IL-1 system may lead to diseases such as psoriasis, atopic dermatitis, contact dermatitis and cutaneous lupus erythematosus. These inflammatory skin conditions greatly affect quality of life and life expectancy, and their frequencies are increasing. However, treatment options for these diseases are unsatisfactory. This review briefly summarizes new findings, reported in the past 2 years, implicating IL-1 family members in skin inflammation. Furthermore, how the biological activities of the IL-1 family members may be inhibited is discussed.
Identifiers
21157640PMC3059231W156240486What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.